Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

GTBP stock hub

GT Biopharma, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

GTBPis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

11.8M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

GTBP

In the news

Latest news · GTBP

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.6P50 18.3P75 33.7

Trailing P/En/a

P25 15P50 23.3P75 38.5

ROE-1,377.4

P25 -106.6P50 -46.9P75 -3.1

ROIC-377.2

P25 -63.1P50 -27.5P75 -0

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All GTBP market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

174

Groups with data

Currency

USD

Showing 174 of 174 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000109657
Company name	GT Biopharma, Inc.
Country	United States
Country code	US
Cusip	36254L209
Employees	1
Employees Change	-1%
Employees Change Percent	-50
Enterprise value	$5M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US36254L3087
Last refreshed	2026-05-10
Market cap	$11.8M
Market cap category	Nano-Cap
Price	$0.38
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	GTBP
Website	https://www.gtbiopharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-290.98%
FCF yield	-109.08%
P/B ratio	1.66x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-34.4M
Net Income Growth Years	0%
Profit Per Employee	$-34.4M
ROA	-125.9
Roa5y	-104.6
ROCE	-214.7
ROE	-1,377.4
ROIC	-377.2

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-70.04%
Cagr15y	-65.9%
Cagr1y	-84.22%
Cagr20y	-58.37%
Cagr3y	-65.31%
Cagr5y	-76.25%
EPS Growth Years	1
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$8.1M
Cash	$6.8M
Current Assets	$8.1M
Current Liabilities	$2.3M
Equity	$5.8M
Interest Coverage	-97.81
Liabilities	$2.3M
Long Term Assets	$0
Long Term Liabilities	$0
Net Cash	$6.8M
Net Cash By Market Cap	$57.53
Net Cash Growth	72.39%
Net Debt Equity	$-1.18
Tangible Book Value	$5.8M
Tangible Book Value Per Share	$0.23
WACC	7.76

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.5
Net Working Capital	$-1M
Quick ratio	2.94
Working Capital	$5.8M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-190.57%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-100%
1Y total return	-84.2%
200-day SMA	0.74
3Y total return	-95.83%
50-day SMA	0.4
50-day SMA vs 200-day SMA	50under200
5Y total return	-99.92%
All Time High	1,634,615,384.6
All Time High Change	-100%
All Time High Date	1991-11-08
All Time Low	0.26
All Time Low Change	43.75%
All Time Low Date	2026-04-29
ATR	0.03
Beta	0.64
Beta1y	-0.05
Beta2y	0.44
Ch YTD	-52.22
High	0.39
High52	3.85
High52 Date	2025-06-27
High52ch	-90.25%
Low	0.37
Low52	0.26
Low52 Date	2026-04-29
Low52ch	43.76%
Ma50ch	-7.17%
Premarket Change Percent	0.64
Premarket Price	$0.39
Premarket Volume	5,396
Price vs 200-day SMA	-49.23%
RSI	50.06
RSI Monthly	37.08
RSI Weekly	35.18
Sharpe ratio	-0.98x
Sortino ratio	-1.29
Total Return	-190.57%
Tr YTD	-52.22
Tr15y	-100%
Tr1m	-9.22%
Tr1w	9.26%
Tr3m	-30.38%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Earnings EPS Estimate	$-0.08
Operating Income	$-12.4M

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	30,826,756%
Float Percent	97.7%
Shares Insiders	0.9%
Shares Institutions	3.48%
Shares Out	31,553,892
Shares Qo Q	229.33%
Shares Yo Y	190.57%
Short Float	2.18%
Short Ratio	1.11
Short Shares	2.13

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-13.3M
Average Volume	710,158.35x
Bv Per Share	0.23
Ch10y	-100
Ch15y	-100
Ch1m	-9.22
Ch1w	9.26
Ch1y	-84.2
Ch20y	-100
Ch3m	-30.38
Ch3y	-95.83
Ch5y	-99.92
Ch6m	-39.44
Change	-3.67%
Change From Open	-3.62
Close	0.39
Days Gap	-0.05
Dollar Volume	186,406.1
Earnings Date	2026-05-15
EBIT	$-12.4M
EPS	$-6.25
F Score	2
FCF	$-12.9M
FCF EV Yield	-256.84x
FCF Per Share	$-0.41
Financing CF	15,775,000
Fiscal Year End	December
Founded	1,965
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-02
Last Report Date	2025-12-31
Last Split Date	2024-02-05
Last Split Type	Reverse
Last10k Filing Date	2026-03-02
Ma150	0.58
Ma150ch	-35.67%
Ma20	0.36
Ma20ch	4.95%
Net CF	2,861,000
Next Earnings Date	2026-05-22
Open	0.39
Optionable	No
Position In Range	20
Post Close	0.38
Postmarket Change Percent	5.41
Postmarket Price	$0.4
Pre Close	0.39
Price Date	2026-05-08
Ptbv Ratio	2.05
Relative Volume	0.7x
Share Based Comp	432,000
Tr20y	-100%
Tr6m	-39.44%
Us State	California
Volume	496,818

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does GTBP pay a dividend?

Capital-return profile for this ticker.

Performance

GTBP stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns GTBP?

Insider, institutional, and short-interest positioning.

Institutional ownership

+3.5%

Float: +97.7% of shares outstanding

Insider ownership

+0.9%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

GTBP momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

50.1

Neutral momentum band

Price vs 200-day MA

-49.2%

50/200-day relationship not available

Beta (5Y)

0.64

Less volatile than the market

Sharpe ratio

-0.98

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About GTBP

Hub-level FAQ points readers to the deeper analysis pages.

What is the current GTBP stock rating?

GT Biopharma, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full GTBP analysis?

The full report lives at /stocks/GTBP/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for GTBP?

The latest report frames GTBP around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the GTBP page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.